Carbon ion therapy for bile duct cancer is used in Japan for patients with intrahepatic cholangiocarcinoma that cannot be removed surgically. In a study pooling four Japanese carbon ion centers (J-CROS, Oncotarget 2019), patients with intrahepatic cholangiocarcinoma treated with carbon ions alone, without surgery, had a 2-year overall survival of 53.4% and a median survival of 23.8 months. Since 2022, intrahepatic cholangiocarcinoma that is difficult to cure with surgery has been covered by Japanese national health insurance for particle therapy; overseas patients receive the same treatment on a self-pay basis. This guide covers eligibility, schedule, cost and the documents to prepare. To find out whether treatment may be possible for you, request a consultation on eligibility and cost.
Carbon ion therapy for bile duct cancer: who is eligible?
Bile duct cancer (cholangiocarcinoma) arises in the ducts that carry bile from the liver. By location it is divided into intrahepatic, perihilar and distal cholangiocarcinoma, with gallbladder cancer as a related disease. Surgery is the standard treatment; when surgery is not possible, care is usually built around drug therapy.
Carbon ion beams stop at a set depth and release most of their energy there (the Bragg peak). This allows a high dose to the tumor while limiting the dose to the healthy liver, stomach and bowel. Their strong effect on adenocarcinoma-type tumors, which respond less well to X-rays, is why they draw attention in bile duct cancer. See What Is Carbon Ion Therapy? for the principle.
QST Hospital (National Institutes for Quantum Science and Technology, Chiba) describes eligibility for intrahepatic cholangiocarcinoma as follows.
| Item | QST Hospital criteria | Records to check |
|---|---|---|
| Cancer type | Unresectable or recurrent intrahepatic cholangiocarcinoma | Pathology report, surgical opinion |
| Spread | No lesions outside the liver | Recent CT, MRI, PET-CT |
| Tumor form | Mass-forming type | Original contrast CT/MRI images |
| First choice | Surgery is recommended first when feasible | Surgeon's opinion |
Perihilar tumors have also been treated in Japanese studies, but they often lie near the bowel and come with bile duct narrowing, so physicians assess them carefully. Distal bile duct and gallbladder cancers were not part of the studies below and need individual review. For hepatocellular carcinoma criteria, see liver cancer carbon ion criteria.
What did Japanese multicenter studies show?
The largest data set comes from the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Four Japanese carbon ion centers, including QST Hospital and Gunma University, analyzed patients treated from 2005 to 2016; results were published in Oncotarget in 2019. All 56 patients were treated without surgery: 27 intrahepatic and 29 perihilar. The most common schedule was 76 Gy (RBE) in 20 fractions.
| Outcome | Intrahepatic (27) | Perihilar (29) | All (56) |
|---|---|---|---|
| 1-year survival | 77.8% | 61.1% | 69.7% |
| 2-year survival | 53.4% | 26.3% | 40.9% |
| Median survival | 23.8 months | 12.6 months | 14.8 months |
| Local control | 79.4% at 1 year, 58.2% at 2 years | Treated site | |
The authors reported relatively favorable outcomes in patients who did not have surgery, especially in intrahepatic cholangiocarcinoma. Treatment-related grade 3 or higher toxicity was one case of bile duct narrowing, and no severe stomach or bowel toxicity was reported. Patients with cholangitis before treatment or Child-Pugh B liver function did less well, so controlling cholangitis and protecting liver function beforehand matters. The authors proposed prospective studies combining carbon ions with drug therapy.
Gunma University Heavy Ion Medical Center reported early results in Anticancer Research in 2016: six intrahepatic and one hilar patient treated in 4 or 12 fractions. At analysis, 6 of 7 were alive, median survival was 16 months and the tumor was controlled in 5 of 7. There was no grade 3 or higher toxicity, and one case of duct narrowing improved with supportive care. For large liver tumors, see carbon ion therapy for liver cancer over 10 cm.
How many sessions, and how long a stay in Japan?
The number of sessions depends on tumor location. Intrahepatic tumors away from the bowel may be treated in 4 sessions (about 1 week); tumors close to the bowel are divided into 12 (about 3 weeks) or 20 sessions (about 4 weeks). Each session, including positioning, usually takes around 30 minutes and is painless.
| Step | What happens | Time |
|---|---|---|
| 1. Record review | Coordinator sends images and pathology; first eligibility check | 1–2 weeks |
| 2. First visit | Visit Japan, examination and final decision | 1–3 days |
| 3. Preparation | Immobilization device, planning CT | 1–2 weeks wait |
| 4. Irradiation | 4, 12 or 20 sessions as prescribed | 1–4 weeks |
| 5. Follow-up | Imaging at home hospital, shared with Japan | Regularly (e.g. every 3 months) |
QST Hospital notes about 1–2 weeks of free time between preparation and the first session; patients who go home must return by the day before treatment. Plan for a total stay of roughly 3–6 weeks. See carbon ion therapy treatment period.
What does it cost for overseas patients?
Japan's FY2022 medical fee revision added intrahepatic cholangiocarcinoma that is difficult to cure surgically to insurance coverage for particle therapy, among diseases where improved survival over X-ray therapy was confirmed. Overseas patients are not enrolled in Japanese insurance and pay the full cost.
| Cost item | QST Hospital published fee | Notes |
|---|---|---|
| Carbon ion technical fee | 5.786 million yen (tax included) | Self-pay for overseas patients |
| Hospital stay, tests, visits | 33 yen per medical fee point (tax included) | Varies with stay and tests |
| Medical coordinator | Not included | Varies by provider |
| Flights, lodging, interpreting | Not included | Budget for a 3–6 week stay |
Amounts are from QST Hospital's page for overseas patients (no date shown; checked October 2026). Compare other centers in carbon ion therapy cost in Japan and see Japanese institutions for application routes.
Total cost differs mainly with hospital stay and pre-treatment tests. Contact us for an estimate based on your situation.
Documents and questions to prepare
Stents, bile drainage tubes and cholangitis history strongly affect the decision. Gathering these speeds up the first review.
- Contrast CT/MRI (ideally with MRCP) from the last 1–2 months, original DICOM files
- PET-CT report and images
- Biopsy pathology report (English translation recommended)
- Records of stent or drainage procedures and cholangitis treatment
- Liver tests (bilirubin, albumin, clotting) and tumor markers (CA19-9, CEA)
- Names and dates of drug therapy received
Write down your questions too: is surgery truly not possible, how many sessions are expected, should drug therapy pause, is a stent acceptable, and how follow-up works after returning home. See document checklist.
FAQ
Can carbon ion therapy replace surgery for bile duct cancer?
If surgery is possible, it is recommended first. Carbon ions are an option when surgery is difficult because of location or health, or for recurrence in the liver after surgery.
Can perihilar cholangiocarcinoma be treated?
In the Japanese multicenter study, 29 patients were treated, with 61.1% 1-year survival; cholangitis control and liver function shaped results. Physicians decide case by case based on distance from the bowel.
Can it be combined with chemotherapy?
Japanese researchers proposed combination with drug therapy as the next research step. When to pause and restart drugs is decided by the Japanese team together with your own oncologist.
What are the side effects?
Severe side effects were rare; one case of bile duct narrowing was reported. Mild skin redness is common and usually settles on its own. Liver function is checked regularly after treatment.
How much does treatment in Japan cost?
QST Hospital's technical fee for overseas patients is 5.786 million yen (tax included), with hospital and test costs at 33 yen per point. Flights, lodging and coordinator fees are extra.
Related articles
Wondering if carbon ion therapy is possible for you, and what it costs?
We help you prepare consultations with Japanese institutions and provide medical interpreting.
Free consultationCall +82-2-517-5117Sources
- Kasuya G et al. Carbon-ion radiotherapy for cholangiocarcinoma: a multi-institutional study by the Japan Carbon-Ion Radiation Oncology Study Group (J-CROS). Oncotarget 2019;10:4369-4379
- Abe T et al. Initial Results of Hypofractionated Carbon Ion Radiotherapy for Cholangiocarcinoma. Anticancer Res 2016;36:2955-2960
- QST Hospital — Indications: liver (hepatocellular carcinoma, intrahepatic bile duct cancer, liver metastases)
- QST Hospital — For Patients from Abroad (fees, procedure)
- FY2022 medical fee revision overview: particle therapy coverage expansion (Japanese, Fukui Prefecture)
General information based on public sources; not a substitute for diagnosis or treatment. Eligibility is decided by the treating physicians. Written by the FTH editorial team.